Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment

BACKGROUND: Significant peripheral blood CD4+ T-cell depletion has been observed after a first cycle of rituximab, a monoclonal antibody directed against the CD20 antigen, which is currently used in rheumatoid arthritis. Of note, an absence of CD4+ T-cell decrease has been observed in non-responders...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavielle, Matthieu, Mulleman, Denis, Goupille, Philippe, Bahuaud, Clément, Sung, Hsueh Cheng, Watier, Hervé, Thibault, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086062/
https://www.ncbi.nlm.nih.gov/pubmed/27793209
http://dx.doi.org/10.1186/s13075-016-1152-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086062/
https://www.ncbi.nlm.nih.gov/pubmed/27793209
http://dx.doi.org/10.1186/s13075-016-1152-5

Ejemplares similares